Resources
8 Results (showing 1 - 8)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 4/14/2021 (updated 4/5/2024)
Learning Objectives
Update milestones and due dates for Implementation and MAT Expansion annual RCORP sustainability deliverables.
Review the calendar of the upcoming sustainability webinar series
Re)Introduce Essential Elements of Sustainability
Interventions to help ensure sustainability of prevention, treatment, and recovery activities via insurance, federal, state, and foundation funding.
Posted 8/4/2021 (updated 4/2/2024)
This session provided an opportunity to learn how to encourage faith leaders how to engage in harm reduction activities.
Posted 4/2/2020 (updated 3/28/2024)
Funding Stability (Sustainability) Webinar Recording and Resources from March 10, 2020.
Posted 1/16/2020 (updated 3/28/2024)
Health care is currently in the middle of a transition from a system of payment based on the volume of services provided (fee-for-service) to payment based on the value of those services (value-based care and alternative payment models).
Posted 4/27/2020 (updated 3/28/2024)
The Advanced Primary Care-Alternative Payment Model (APC-APM) embodies the principle that patient-centered primary care is comprehensive, continuous, coordinated, connected, and accessible from the patient’s first contact with the health system.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.